Condition: Social Anxiety Disorder · Sponsor: VistaGen Therapeutics, Inc.
This U.S. multicenter, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate the efficacy, safety, and tolerability of a repeat intranasal (i.n.) dose of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months, will be assessed in those subjects who complete PH94B-CL036 and choose to enter the distinct open-label extension phase of the study.
This description comes directly from the study's public registry record.
Clinical Studies Vistagen Therapeutics, Inc. · 650-577-3693 · clinicalstudies@vistagen.com
Always discuss trial participation with your own doctor first.
| Vistagen Clinical Site | Sherman Oaks, California, United States | Recruiting |
| Vistagen Clinical Site | Walnut Creek, California, United States | Recruiting |
| Vistagen Clinical Site | Largo, Florida, United States | Recruiting |
| Vistagen Clinical Site | Saint Charles, Missouri, United States | Recruiting |
| Vistagen Clinical Site | Toms River, New Jersey, United States | Recruiting |
| Vistagen Clinical Site | Cary, North Carolina, United States | Recruiting |
| Vistagen Clinical Site | Cleveland, Ohio, United States | Terminated |
| Vistagen Clinical Site | Plymouth Meeting, Pennsylvania, United States | Recruiting |
| Vistagen Clinical Site | Plano, Texas, United States | Terminated |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06809179